Laduviglusib,IC-0121293
Laduviglusib (CHIR-99021) is a potent, selective and orally active GSK-3¦Á/¦Â inhibitor with IC50s of 10 nM and 6.7 nM. Laduviglusib shows >500-fold selectivity for GSK-3 over CDC2, ERK2 and other protein kinases. Laduviglusib is also a potent Wnt/¦Â-catenin signaling pathway activator. Laduviglusib enhances mouse and human embryonic stem cells self-renewal. Laduviglusib induces autophagy[1][2][3].
Cell Viability Assay[2]
| Cell Line: | ES-D3 cells |
| Concentration: | 1-10 ¦̀M |
| Incubation Time: | 3 days |
| Result: | Reduced the viability of the ES-D3 cells by 24.7% at 2.5 ¦̀M, 56.3% at 5 ¦̀M, 61.9% at 7.5 ¦̀M and 69.2% at 10 ¦̀M |
| Animal Model: | ZDF rats[1] |
| Dosage: | 30 mg/kg |
| Administration: | Oral administration |
| Result: | Lowered plasma glucose, with a maximal reduction of nearly 150 mg/dl 3-4 h after administration. |
| Animal Model: | WT C57BL/6 mice[5] |
| Dosage: | 2 mg/kg |
| Administration: | Intraperitoneal injection (i.p.) |
| Result: | Blocked crypt apoptosis and increased Lgr5+ cell survival. |
[2]. Naujok O, et al. Cytotoxicity and activation of the Wnt/beta-catenin pathway in mouse embryonic stem cells treated with four GSK3 inhibitors.BMC Res Notes. 2014 Apr 29;7:273.
[3]. Ye S, et al. Pleiotropy of glycogen synthase kinase-3 inhibition by CHIR99021 promotes self-renewal of embryonic stem cells from refractory mouse strains. PLoS One. 2012;7(4):e35892.
[4]. Bennett CN, et al. Regulation of Wnt signaling during adipogenesis. J Biol Chem. 2002 Aug 23;277(34):30998-1004.
[5]. Wang X, et al. Pharmacologically blocking p53-dependent apoptosis protects intestinal stem cells and mice from radiation. Sci Rep. 2015 Apr 10;5:8566.
|
Order Information |
|||||
|
Cat./REF. |
Size |
Price($£© |
Price(€) |
Price(£¤/CNY£© |
Price(£¤/JYP£© |
|
IC-0121293 |
5mg |
$120.00 |
€ 144.00 |
£¤1,200.00 |
£¤23,880.00 |
|
IC-0121293 |
25mg |
$480.00 |
€ 576.00 |
£¤4,800.00 |
£¤95,520.00 |
|
IC-0121293 |
100mg |
$1,440.00 |
€ 1,728.00 |
£¤14,400.00 |
£¤286,560.00 |
